OncoMatch/Clinical Trials/NCT06225804
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer
Is NCT06225804 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies ABSK112 for non-small cell lung cancer.
Treatment: ABSK112 — This is a first-in-human (FIH), multicenter, non-randomized, openlabel, phase 1 study of ABSK112 in patients with NSCLC to evaluate the safety, tolerability, PK, and preliminary antitumor efficacy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR in-frame exon 20 insertion mutation
documented EGFR in-frame exon 20 insertion mutations confirmed by certificated local laboratories
Excluded: EGFR C797S mutation
NSCLC patients with EGFR Cys797Ser (C797S) mutation
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard therapy
patients have progressed on, rejected, or are intolerant of standard therapy, or for whom no standard therapy exists
Cannot have received: anti-cancer therapy
Previous anti-cancer therapy, including chemotherapy, radiotherapy, molecular targeted therapy, antibody therapy or other investigational drugs received ≤4 weeks prior to initiation of study treatment
Lab requirements
Blood counts
adequate bone marrow function
Kidney function
adequate organ function
Liver function
adequate organ function
Adequate organ function and bone marrow function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Precision NextGen Oncology · Beverly Hills, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify